drugset / Trial / NCT01569516

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

NCT01569516

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.

Timeline

Start
2011-06
Primary completion
2012-07
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Subject OCTAAMINOACRIDINE Small molecule 1 mg
Subject OCTAAMINOACRIDINE Small molecule 2 mg
Subject OCTAAMINOACRIDINE Small molecule 4 mg

Indications